Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 22Immunoglobulin Light-chain Amyloidosis 4Waldenstrom Macroglobulinemia 3Recurrence 2Lymphoma, T-Cell, Peripheral 2Smoldering Multiple Myeloma 1Sarcoma, Kaposi 1Proteostasis Deficiencies 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms, Plasma Cell 1Neoplasms 1Neoplasm, Residual 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hematologic Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Amyloidosis 1

Interventions

Dexamethasone 4Cyclophosphamide 4Bortezomib 3daratumumab 2belantamab mafodotin 2venetoclax 1pegfilgrastim 1ixazomib 1dexamethasone acetate 1dexamethasone 21-phosphate 1auricularum 1Lenalidomide 1Calcium Dobesilate 1Antineoplastic Protocols 14-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Amyloidosis × ixazomib × 1 year × Clear all
NCT01864018 2025-07-24

Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis

Mayo Clinic

Phase 1/2 Completed
87 enrolled 13 charts
Plasma cell

Amyloidosis, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡